ArticleMolecular cancer therapeutics2026
Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605.
Article in Molecular cancer therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Velcrin compounds kill cancer cells expressing elevated levels of two cellular proteins, the PDE3A phosphodiesterase and the SLFN12 tRNase, by inducing PDE3A-SLFN12 complex formation. This results in activation of SLFN12, leading to digestion of its specific substrate, tRNA-Leu-TAA, inhibition of protein synthesis, and cell death, a process now called "tomoptosis". We hypothesized that velcrins such as BAY 2666605, a clinical velcrin, could be active against biomarker-positive uveal melanomas. We identified uveal melanoma cell lines expressing elevated levels of the biomarkers, PDE3A and SLFN12, and tested response to velcrin compounds in vitro and in vivo. We show that response correlates mechanistically with decreased levels of tRNA-Leu-TAA and inhibition of nascent protein synthesis and furthermore identify a potential mechanism of resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.